[{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA-A receptor; anion channel | Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eurofarma Laboratorios S.A","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Codeine","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"N0728","moa":"Undisclosed","graph1":"Urology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"N0892","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"N0877","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"N0750","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BRAZIL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Progestogen","moa":"Progesterone receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"Cyclooxygenase-2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Bovine Heparin Sodium","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Eurofarma Laboratorios S.A

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          April 01, 2025

                          Lead Product(s) : Progestogen

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : N0750

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 23, 2024

                          Lead Product(s) : N0877

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 19, 2024

                          Lead Product(s) : N0892

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : N0728

                          Therapeutic Area : Urology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 31, 2024

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 21, 2023

                          Lead Product(s) : Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 13, 2023

                          Lead Product(s) : Etoricoxib

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 05, 2022

                          Lead Product(s) : Levocetirizine Dihydrochloride

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the terms of agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize Xcopri (cenobamate) in Latin America. SK Biopharmaceuticals will now be present in four continents: North America, Europe, Asia, a...

                          Product Name : Xcopri

                          Product Type : Controlled Substance

                          Upfront Cash : $15.0 million

                          July 14, 2022

                          Lead Product(s) : Cenobamate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : SK Biopharmaceuticals

                          Deal Size : $62.0 million

                          Deal Type : Licensing Agreement

                          blank